MA30558B1 - Antagonistes de recepteurs cgrp monocycliques substitues - Google Patents

Antagonistes de recepteurs cgrp monocycliques substitues

Info

Publication number
MA30558B1
MA30558B1 MA31438A MA31438A MA30558B1 MA 30558 B1 MA30558 B1 MA 30558B1 MA 31438 A MA31438 A MA 31438A MA 31438 A MA31438 A MA 31438A MA 30558 B1 MA30558 B1 MA 30558B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
cgrp receptor
substituted monocyclic
cgrp
compounds
Prior art date
Application number
MA31438A
Other languages
English (en)
Inventor
Michael R Wood
Ian M Bell
Steven N Gallicchio
Harold G Selnick
Craig A Stump
C Blair Zartman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30558B1 publication Critical patent/MA30558B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule I : (dans laquelle les variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG et Y sont comme est décrit ici) qui sont des antagonistes des récepteurs du CGRP et qui sont utiles dans le traitement ou la prévention de maladies dans lesquelles le CGRP est impliqué, telles que la migraine. L'invention concerne aussi des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles le CGRP est impliqué.
MA31438A 2006-05-09 2008-12-04 Antagonistes de recepteurs cgrp monocycliques substitues MA30558B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79907106P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
MA30558B1 true MA30558B1 (fr) 2009-07-01

Family

ID=38556368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31438A MA30558B1 (fr) 2006-05-09 2008-12-04 Antagonistes de recepteurs cgrp monocycliques substitues

Country Status (23)

Country Link
US (3) US7629338B2 (fr)
EP (2) EP2029575B1 (fr)
JP (2) JP4435288B2 (fr)
KR (1) KR20090018107A (fr)
CN (1) CN101443323A (fr)
AR (1) AR060872A1 (fr)
AU (1) AU2007284994B2 (fr)
BR (1) BRPI0711352A2 (fr)
CA (1) CA2650932C (fr)
CR (1) CR10415A (fr)
DO (1) DOP2007000093A (fr)
EA (1) EA200870521A1 (fr)
EC (1) ECSP088872A (fr)
GE (1) GEP20115140B (fr)
HN (1) HN2008001667A (fr)
IL (1) IL195110A0 (fr)
MA (1) MA30558B1 (fr)
MX (1) MX2008014353A (fr)
NO (1) NO20085110L (fr)
PE (1) PE20080253A1 (fr)
TW (1) TW200813008A (fr)
WO (2) WO2008020902A1 (fr)
ZA (1) ZA200809275B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580020A1 (fr) * 2004-09-09 2006-03-23 Ian M. Bell Antagonistes des recepteurs cgrp d'aryle-spirolactame
AU2005285109B2 (en) * 2004-09-13 2011-03-03 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
WO2008020902A1 (fr) * 2006-05-09 2008-02-21 Merck & Co., Inc. Antagonistes spirocycliques substitués des récepteurs cgrp
EP2091533B1 (fr) 2006-12-08 2012-11-28 Merck Sharp & Dohme Corp. Composés spirocycliques contraints servant d'antagonistes des récepteurs du cgrp
WO2008112159A2 (fr) 2007-03-12 2008-09-18 Merck & Co., Inc. Antagonistes des récepteurs cgrp d'anilide spirolactame monocyclique
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
US8173655B2 (en) 2007-04-16 2012-05-08 Merck, Sharp & Dohme Corp. Bicyclic anilide heterocyclic CGRP receptor antagonists
WO2008130524A1 (fr) * 2007-04-16 2008-10-30 Merck & Co., Inc. Antagonistes des récepteurs du cgrp aryl hétérocycliques
WO2008153849A1 (fr) * 2007-06-05 2008-12-18 Merck & Co., Inc. Antagonistes des récepteurs cgrp à base de carboxamide hétérocyclique
JP2010529120A (ja) 2007-06-07 2010-08-26 メルク・シャープ・エンド・ドーム・コーポレイション 三環式アニリド複素環ｃｇｒｐ受容体アンタゴニスト
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
CA2711367A1 (fr) * 2008-02-19 2009-08-27 Merck Sharp & Dohme Corp. Antagonistes de recepteurs de cgrp de type imidazobenzazepine
JP2011515480A (ja) * 2008-03-28 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 単環式ｃｇｒｐ受容体アンタゴニスト
JP2012511500A (ja) * 2008-08-20 2012-05-24 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストとしての分岐末端を有する非アミドリンカー
CA2735821A1 (fr) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Antagonistes du recepteur cgrp d'amide monocyclique
CA2737711A1 (fr) * 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Antagonistes des recepteurs du cgrp a base de dihydroimidazolone bicyclique
JP2012504625A (ja) * 2008-10-03 2012-02-23 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニスト
AU2009302712A1 (en) * 2008-10-10 2010-04-15 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2010077752A1 (fr) 2008-12-17 2010-07-08 Merck Sharp & Dohme Corp. Dérivés d'imidazolinone en tant qu'antagonistes de récepteurs cgrp
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
WO2011005731A2 (fr) 2009-07-08 2011-01-13 Merck Sharp & Dohme Corp. Procédé de production d'antagoniste du récepteur cgrp
EP2458991A4 (fr) * 2009-07-27 2012-12-12 Merck Sharp & Dohme Antagonistes radio-marqués du cgrp
CA2798831A1 (fr) 2010-05-11 2011-11-17 Pfizer Inc. Composes morpholiniques convenant comme antagonistes de recepteurs de mineralcorticoides
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2654421B1 (fr) 2010-12-22 2016-10-19 Merck Sharp & Dohme Corp. Indanecarboxamides condensés comme antagonistes des récepteurs du cgrp
AU2012231293A1 (en) * 2011-03-18 2013-08-29 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin CGRP receptor antagonists
EP2685826B1 (fr) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
KR20220164616A (ko) * 2012-03-14 2022-12-13 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제의 제조 방법
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2013169567A1 (fr) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Antagonistes de récepteur de cgrp à base de spirolactame
EP2846798B1 (fr) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Antagonistes de récepteur de cgrp à base de spirolactame aliphatique
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
PE20161405A1 (es) * 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102448369B1 (ko) 2014-02-05 2022-09-28 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
EP3313518A1 (fr) * 2015-06-29 2018-05-02 Galderma Research & Development Composés d'antagoniste de récepteur cgrp pour le traitement topique de troubles cutanés
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
EP3366286A1 (fr) 2017-02-22 2018-08-29 Johannes Keller Composés destinés au traitement de septicémie
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
AU2019207915B2 (en) 2018-01-12 2025-09-04 Amgen Inc. PAC1 antibodies and uses thereof
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
EP4301362A1 (fr) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Traitement et/ou réduction de l'apparition de migraine
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023208124A1 (fr) * 2022-04-29 2023-11-02 熙源安健医药（上海）有限公司 Dérivé d'azaindane de pipéridine carboxamide, son procédé de préparation et son utilisation
WO2024134683A1 (fr) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Nouvelle méthode de préparation de composés intermédiaires utilisés dans le traitement de la migraine
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
CN118930542A (zh) * 2024-07-25 2024-11-12 电子科技大学长三角研究院(衢州) 抗猴痘病毒和天花病毒的新型结构化合物及其组合应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JP2001294574A (ja) * 2000-04-11 2001-10-23 Suntory Ltd カルシトニン受容体作動物質
EP1606286B1 (fr) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
CA2518852A1 (fr) * 2003-03-14 2004-09-30 Merck & Co., Inc. Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
US7202251B2 (en) 2003-03-14 2007-04-10 Merck & Co., Inc. Bicyclic anilide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
DE602004027021D1 (de) 2003-04-15 2010-06-17 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
AU2004252150B2 (en) 2003-06-26 2008-11-20 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
ATE461196T1 (de) 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
JP4705922B2 (ja) * 2004-01-29 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
CA2579221A1 (fr) 2004-09-08 2006-03-16 Merck & Co., Inc. Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
CA2579717A1 (fr) 2004-09-09 2006-03-23 Merck & Co., Inc. Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
CA2580020A1 (fr) 2004-09-09 2006-03-23 Ian M. Bell Antagonistes des recepteurs cgrp d'aryle-spirolactame
ATE518852T1 (de) 2004-09-13 2011-08-15 Merck Sharp & Dohme Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
AU2005285109B2 (en) 2004-09-13 2011-03-03 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
JP2008515895A (ja) 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
MX2007004393A (es) 2004-10-13 2007-04-25 Merck & Co Inc Antagonistas del receptor a peptido relacionado con el gen calcitonina.
JP2008516957A (ja) * 2004-10-14 2008-05-22 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
DE602005027230D1 (de) 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
EP1856100B1 (fr) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Antagonistes de recepteurs du peptide lie au gene de la calcitonine (cgrp)
ATE537170T1 (de) 2005-03-14 2011-12-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
WO2007016087A2 (fr) 2005-07-29 2007-02-08 Merck & Co., Inc. Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
AU2006316646A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam bicyclic CGRP receptor antagonists
EP1951042B1 (fr) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Antagonistes du récepteur cgrp spirolactame tricycliques
CA2629421A1 (fr) 2005-11-18 2007-05-31 Merck & Co., Inc. Antagonistes du recepteur cgrp tricyclique de la spirohydantoine
WO2007061677A2 (fr) 2005-11-18 2007-05-31 Merck & Co., Inc. Antagoniste du recepteur cgpr de spirolactam aryle
EP1963532A4 (fr) 2005-12-07 2010-07-21 Univ Utah Res Found Methylation de l'adn en tant que cible pour le diagnostic et le traitement de la leucemie lymphocytaire chronique (llc)
WO2008020902A1 (fr) 2006-05-09 2008-02-21 Merck & Co., Inc. Antagonistes spirocycliques substitués des récepteurs cgrp
CA2658573A1 (fr) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Antagonistes des recepteurs cgrp
WO2008112159A2 (fr) 2007-03-12 2008-09-18 Merck & Co., Inc. Antagonistes des récepteurs cgrp d'anilide spirolactame monocyclique
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
US8173655B2 (en) 2007-04-16 2012-05-08 Merck, Sharp & Dohme Corp. Bicyclic anilide heterocyclic CGRP receptor antagonists

Also Published As

Publication number Publication date
JP2009536645A (ja) 2009-10-15
HN2008001667A (es) 2011-07-22
WO2007133491A1 (fr) 2007-11-22
JP4435288B2 (ja) 2010-03-17
AR060872A1 (es) 2008-07-16
US20100056498A1 (en) 2010-03-04
EA200870521A1 (ru) 2009-04-28
US7629338B2 (en) 2009-12-08
US7625901B2 (en) 2009-12-01
US20070265225A1 (en) 2007-11-15
EP2024358B1 (fr) 2014-11-05
BRPI0711352A2 (pt) 2011-09-27
EP2029575B1 (fr) 2014-10-22
PE20080253A1 (es) 2008-04-05
CA2650932A1 (fr) 2008-02-21
MX2008014353A (es) 2008-11-24
CA2650932C (fr) 2013-01-22
TW200813008A (en) 2008-03-16
IL195110A0 (en) 2009-09-22
ZA200809275B (en) 2009-10-28
JP2010013449A (ja) 2010-01-21
EP2029575A1 (fr) 2009-03-04
DOP2007000093A (es) 2008-01-15
ECSP088872A (es) 2008-12-30
EP2024358A1 (fr) 2009-02-18
AU2007284994A1 (en) 2008-02-21
KR20090018107A (ko) 2009-02-19
AU2007284994B2 (en) 2010-04-22
CR10415A (es) 2009-01-27
GEP20115140B (en) 2011-01-10
NO20085110L (no) 2009-02-06
US7893079B2 (en) 2011-02-22
WO2008020902A1 (fr) 2008-02-21
CN101443323A (zh) 2009-05-27
US20080318927A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
MA30558B1 (fr) Antagonistes de recepteurs cgrp monocycliques substitues
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
WO2006029153A3 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
NO20072435L (no) CGRP-reseptorantagonister
MA30999B1 (fr) Composés.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE466860T1 (de) Cgrp-rezeptorantagonisten
MA31683B1 (fr) Composes et procedes pour moduler fxr
WO2005000807A3 (fr) Antagonistes du recepteur cgrp de benzodiazepine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
EP1794133A4 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame
PT1716152E (pt) Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
ATE529107T1 (de) Ligustilid-derivate zur behandlung von entzündungserkrankungen
DE602006019304D1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007146349A3 (fr) Antagonistes du récepteur du cgrp